Model-informed COVID-19 vaccine prioritization strategies by age and serostatus.
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
26 02 2021
26 02 2021
Historique:
received:
08
09
2020
accepted:
12
01
2021
pubmed:
23
1
2021
medline:
6
3
2021
entrez:
22
1
2021
Statut:
ppublish
Résumé
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Identifiants
pubmed: 33479118
pii: science.abe6959
doi: 10.1126/science.abe6959
pmc: PMC7963218
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
916-921Subventions
Organisme : NCI NIH HHS
ID : U01 CA261277
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Informations de copyright
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
BMJ Glob Health. 2020 Sep;5(9):
pubmed: 32912856
Aging (Albany NY). 2020 May 29;12(10):9959-9981
pubmed: 32470948
Science. 2020 Nov 13;370(6518):763-765
pubmed: 33087460
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Prod Oper Manag. 2018 Jan;27(1):143-159
pubmed: 32327917
JAMA. 1994 Dec 7;272(21):1661-5
pubmed: 7966893
PLoS Comput Biol. 2021 Jul 26;17(7):e1009098
pubmed: 34310590
Science. 2009 Sep 25;325(5948):1705-8
pubmed: 19696313
JAMA Intern Med. 2020 Aug 1;180(8):1041-1042
pubmed: 32343355
Ann Intern Med. 1995 Oct 1;123(7):518-27
pubmed: 7661497
Nature. 2020 Apr;580(7805):578-580
pubmed: 32273621
Nat Commun. 2020 Aug 13;11(1):4049
pubmed: 32792562
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
PLoS Med. 2006 Oct;3(10):e387
pubmed: 17020406
Vaccines (Basel). 2018 May 21;6(2):
pubmed: 29883414
Expert Rev Vaccines. 2018 May;17(5):435-443
pubmed: 29715054
Eur Respir J. 2020 May 27;55(5):
pubmed: 32312864
Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):
pubmed: 33811185
mBio. 2020 Sep 18;11(5):
pubmed: 32948688
Euro Surveill. 2021 Feb;26(8):
pubmed: 33632374
BMC Med. 2020 May 7;18(1):124
pubmed: 32375776
Virology. 2006 Aug 15;352(1):216-25
pubmed: 16725169
Science. 2020 Jun 26;368(6498):1481-1486
pubmed: 32350060
Lancet Infect Dis. 2021 Jul;21(7):962-974
pubmed: 33743846
Euro Surveill. 2022 Mar;27(9):
pubmed: 35241216
Vaccine. 2005 Jan 26;23(10):1284-93
pubmed: 15652671
J Infect Dis. 2021 Feb 13;223(3):362-369
pubmed: 33119738
Elife. 2021 Mar 05;10:
pubmed: 33666169
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Immunology. 2020 Jul;160(3):223-232
pubmed: 32460358
mBio. 2017 Nov 21;8(6):
pubmed: 29162706
Commun Biol. 2020 Jul 8;3(1):374
pubmed: 32641750
Science. 2020 Jul 3;369(6499):15-16
pubmed: 32631874
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
CMAJ. 2020 Jun 22;192(25):E684-E685
pubmed: 32493741
Sci Adv. 2021 Feb 3;7(6):
pubmed: 33536223
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864